Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Nutrition & Metabolism

Figure 1

From: Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics

Figure 1

Fasting and postprandial insulin and glucose levels in diabetics plus ROSI treatment: Following a standardized mixed meal, arterial insulin (A), arterial glucose (B) and adipose tissue venous glucose (C) were measured serially from 0 to 6 hours in control (n = 9), diabetics (n = 6) and diabetics treated with rosiglitazone (ROSI). Results are expressed as average ± sem with detailed statistics presented in the text, all comparisons used RM-ANOVA.

Back to article page